Latest Breaking News On - Acute care nephrology - Page 2 : comparemela.com

BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference

November 1, 2023 News Release BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, that it will present two poster presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2023. Both poster presenta

United statesStuartl goldsteinAshley robinsonTabari bakerTim eriksenBioportoas bioporto or companyGlobal medical affairsPennsylvania convention centerAmerican society of nephrologyPorto announces two poster presentationsAcute kidney injuryAmerican societyKidney weekAcute care nephrologyCincinnati childrenHospital medical center

BioPorto Announces Two Poster Presentations at ASN Kidney

November 1, 2023 News Release BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference COPENHAGEN,.

United statesTabari bakerStuartl goldsteinTim eriksenAshley robinsonAmerican society of nephrologyBioportoas bioporto or companyPennsylvania convention centerGlobal medical affairsPorto announces two poster presentationsAcute kidney injuryAmerican societyKidney weekAcute care nephrologyCincinnati childrenHospital medical center

SeaStar Medical (ICU) Reports Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

SeaStar Medical (ICU) Reports Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesStuart goldsteinImmunomodulatory dysregulationSeastar medical holding corporation nasdaqAmerican society of nephrologyCenter study to assess the safetyStar medical holding corporationAmerican societyKidney weekMulti center studySelective cytopheretic deviceReport fromAcute care nephrologyCincinnati childrenRisk factorsSeastar medical

SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children Seite 1

03.11.2022 - Data being presented at the American Society of Nephrology (ASN) Kidney Week 2022 Interim study data show that SCD treatment is safe to use in pediatric patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) . Seite 1

United statesStuart goldsteinImmunomodulatory dysregulationAmerican society of nephrologySeastar medicalholding corporation nasdaqCenter study to assess the safetySeastar medicalholding corporationAmerican societyKidney weekMulti center studySelective cytopheretic deviceReport fromAcute care nephrologyCincinnati childrenRisk factorsSeastar medical nasdaq

AcelRx Pharmaceuticals Stock: Finally, Plan B (NASDAQ:ACRX)

Without knowledge of the DSUVIA deal it is hard to assess the prospect, so I retain a neutral rating with a tilt to buy. Read more about ACRX stock here.

South koreaUnited statesVadzim kushniarouEin geschB das konzeptNafamostat niyadVincent angottiNiyad nafamostatClinical development of niyadDepartment of anesthesiologyDivision of renal diseasesAscs ambulatory surgical centersGeorge washington universityAcelrx pharmaceuticals incLowell therapeutics incUs army